CareDx, Inc
8000 Marina Boulevard
Brisbane
South San Francisco, CA 94005
United States
415 287 2300
https://caredx.com
版塊: Healthcare
行業: Diagnostics & Research
全職員工: 635
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Abhishek Jain | CFO & Principal Accounting Officer | 688.12k | 無 | 1977 |
| Dr. Peter Maag Ph.D. | Executive Director | 54.94k | 無 | 1967 |
| Mr. Alexander L. Johnson | President of Patient & Testing Services | 690.85k | 無 | 1975 |
| Mr. John Walter Hanna Jr. | President, CEO & Director | 無 | 無 | 1980 |
| Ms. Marica Grskovic Ph.D. | Chief Operating Officer | 無 | 無 | 無 |
| Dr. Robert N. Woodward Ph.D. | Chief Scientific Officer | 無 | 無 | 無 |
| Mr. GS Jha | Senior VP, Chief Information Officer & Chief Information Security Officer | 無 | 無 | 無 |
| Mr. Jeffrey A. Novack | General Counsel & Secretary | 無 | 無 | 1983 |
| Ms. Stacey Follon | Senior VP & Head of Human Resources | 無 | 無 | 無 |
| Mr. Kashif Rathore | Chief of Patient & Digital Solutions | 無 | 無 | 無 |
描述
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
公司管治
截至 2024年6月1日 止，CareDx, Inc 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：10；董事會：3；股東權利：5；現金賠償：6。
